ST. LOUIS & HERCULES, Calif.--(

加利福尼亚州圣路易斯和大力士--(

BUSINESS WIRE

商业热线

)--

)--

Geneoscopy, Inc.

Geneoscopy公司。

, a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the closing of a Series C funding round raising $105 million. Bio-Rad Laboratories (NYSE: BIO and BIO.B) led the financing and was joined by Petrichor, Labcorp (NYSE: LH), Morningside Ventures, Lightchain Capital, NT Investments, Granger Management and Mercy Health, Tri Locum Partners, and others..

，一家专注于开发诊断测试以促进胃肠健康的生命科学公司，今天宣布结束一轮C系列融资，融资1.05亿美元。Bio-Rad Laboratories（纽约证券交易所代码：Bio和Bio.B）牵头融资，加入的有Petrichor、Labcorp（纽约证券交易所代码：LH）、Morningside Ventures、Lightchain Capital、NT Investments、Granger Management and Mercy Health、Tri-Locom Partners等。

The capital raise positions the company to achieve key milestones, including the launch and commercialization of Geneoscopy’s at-home, stool-based colorectal cancer screening test,

此次融资使该公司能够实现关键的里程碑，包括在家中推出和商业化基于粪便的结直肠癌筛查测试，

ColoSense

歌罗西书

. The funding also enables the company to continue investing in its innovative pipeline of diagnostic tests for inflammatory bowel disease, addressing a critical unmet medical need.

。这笔资金还使该公司能够继续投资于其创新的炎症性肠病诊断测试管道，以解决尚未满足的关键医疗需求。

Geneoscopy’s novel platform for isolating human RNA from stool samples, combined with the high sensitivity and specificity of

Geneoscopy从粪便样本中分离人类RNA的新型平台，结合了

Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology

Bio-Rad的Droplet Digital™PCR（ddPCR™）技术

, allows for highly effective screening and detection of colorectal cancer. Further,

，可以高效筛查和检测结直肠癌。此外，

Geneoscopy and Labcorp will work together

Geneoscopy和Labcorp将合作

to provide broad availability of ColoSense, enabling healthcare providers to conveniently order the test as part of their comprehensive screening programs.

提供ColoSense的广泛可用性，使医疗保健提供者能够方便地订购测试作为其综合筛查计划的一部分。

“This past year, we achieved many significant milestones, most notably FDA approval of ColoSense,” said Andrew Barnell, CEO and co-founder of Geneoscopy. “We are extremely pleased to secure this financing, which reflects investor confidence in the potential of our RNA technology to address unmet needs in colorectal cancer and inflammatory bowel disease.

Geneoscopy首席执行官兼联合创始人安德鲁·巴内尔（AndrewBarnell）表示：“在过去的一年中，我们取得了许多重要的里程碑，最值得一提的是FDA批准了ColoSense。”。“我们非常高兴获得这笔资金，这反映了投资者对我们的RNA技术在解决结直肠癌和炎症性肠病未满足需求方面的潜力的信心。

This continued support will enable us to deliver innovative solutions that prioritize patient well-being and shape the future of gastrointestinal health.”.

这种持续的支持将使我们能够提供创新的解决方案，优先考虑患者的福祉，并塑造胃肠健康的未来。”

Norman Schwartz, CEO of Bio-Rad Laboratories, stated, 'As a leader in clinical diagnostics and digital biology, Bio-Rad’s mission is to advance science and save lives by improving healthcare outcomes. Geneoscopy’s ColoSense screening test is designed for use with

Bio-Rad实验室首席执行官诺曼·施瓦茨（NormanSchwartz）表示，“作为临床诊断和数字生物学领域的领导者，Bio-Rad的使命是通过改善医疗保健结果来推进科学和挽救生命。Geneoscopy的ColoSense筛查测试旨在与

Bio-Rad’s QXDx ddPCR platform

Bio-Rad的QXDx ddPCR平台

and demonstrates remarkable sensitivity in detecting colorectal cancer and advanced adenomas. With this investment, we look forward to supporting Geneoscopy’s development and commercialization efforts while advancing our Droplet Digital PCR platform as a foundational technology for oncology applications across the clinical diagnostics and translational research markets.”.

并且在检测结直肠癌和晚期腺瘤方面表现出显着的敏感性。通过这项投资，我们期待着支持Geneoscopy的开发和商业化工作，同时推动我们的液滴数字PCR平台作为临床诊断和转化研究市场肿瘤学应用的基础技术。”

Colorectal cancer is the

结直肠癌是

second deadliest cancer

第二致命的癌症

in the U.S., with incidence

在美国，发病率

rates rising among populations

人口比例上升

under 50 years old. This alarming trend prompted the United States Preventive Services Task Force to lower the recommended age for initial screening to 45. Despite this change, millions of eligible people do not get screened due to a combination of factors such as limited access or avoidance of invasive procedures like colonoscopies.

50岁以下。这一令人担忧的趋势促使美国预防服务工作组将初次筛查的建议年龄降至45岁。尽管发生了这种变化，但数百万符合条件的人由于各种因素的综合作用而无法接受筛查，例如访问受限或避免结肠镜检查等侵入性手术。

Following the successful Series C funding round, Geneoscopy is poised to address these challenges with ColoSense, a promising new tool that detects colorectal cancer early and accurately..

在成功的C系列融资回合之后，Geneoscopy准备用ColoSense来应对这些挑战，ColoSense是一种有前途的早期准确检测结直肠癌的新工具。

Geneoscopy’s CEO, Andrew Barnell, will present a company update and expand on plans for this funding round at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Thursday, Jan. 16, 2025, at 11:30 AM PST / 2:30 PM EST.

Geneoscopy首席执行官安德鲁·巴内尔（AndrewBarnell）将在旧金山举行的第43届摩根大通（J.P.Morgan）医疗保健年会上介绍公司最新情况，并扩大这一融资回合的计划。演讲将于2025年1月16日（星期四）上午11:30（太平洋标准时间）/下午2:30（美国东部标准时间）举行。

About Geneoscopy, Inc.

关于Geneoscopy，Inc。

Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics.

Geneoscopy，Inc.是一家生命科学公司，专注于开发胃肠道健康诊断测试。Geneoscopy利用其专有的专利粪便来源的真核RNA（seRNA）生物标志物平台，其使命是使患者和提供者能够通过创新诊断来改变胃肠道健康。

The company’s .

公司的。

FDA-approved ColoSense test

FDA批准的ColoSense测试

uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas.

使用专有的基于RNA的平台为45岁以上的平均风险人群筛查结直肠癌和晚期腺瘤。Geneoscopy还与领先的大学和生物制药公司合作，为其他胃肠道疾病领域的治疗选择和治疗监测开发诊断测试。

For more information, visit .

有关更多信息，请访问。

www.geneoscopy.com

www.geneoscopy.com

and follow the company on

跟随公司前进

LinkedIn

LinkedIn

.

.

About Bio-Rad Laboratories, Inc.

关于Bio-Rad Laboratories，Inc。

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023.

Bio-Rad Laboratories，Inc.（纽约证券交易所：Bio and Bio.B）是为生命科学研究和临床诊断市场开发、制造和营销多种产品的领导者。Bio-Rad总部位于加利福尼亚州的大力神，拥有全球研发、制造和销售运营网络，2023年拥有约7700名员工和27亿美元的收入。

Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit .

我们的客户包括大学、研究机构、医院和生物制药公司，以及临床、食品安全和环境质量实验室。我们共同开发创新、高质量的产品，以推进科学和拯救生命。要了解更多信息，请访问。

www.bio-rad.com

www.bio-rad.com

.

.

Bio-Rad Forward Looking Statements

Bio-Rad前瞻性声明

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products, Geneoscopy’s ColoSense screening test, and supporting Geneoscopy’s development and commercialization efforts while advancing our droplet digital PCR platform as a foundational technology for oncology applications across the clinical diagnostics and translational research markets.

本公告可能被视为包含1995年《私人证券诉讼改革法案》所指的某些前瞻性声明。这些前瞻性声明包括但不限于我们对产品的期望，Geneoscopy的ColoSense筛查测试，以及支持Geneoscopy的开发和商业化努力，同时推进我们的液滴数字PCR平台作为临床诊断和转化研究市场肿瘤学应用的基础技术。

Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'plan,' 'believe,' 'expect,' 'anticipate,' 'may,' 'will,' 'intend,' 'estimate,' 'continue,' or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words.

前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“计划”，“相信”，“期望”，“预期”，“可能”，“意志”，“打算”，“估计”，“继续”或类似的表达或这些术语或表达的否定，尽管并非所有前瞻性陈述都包含这些单词。

Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues.

此类声明涉及风险和不确定性，这可能导致实际结果与前瞻性声明中表达或指示的结果产生重大差异。这些风险和不确定性包括全球经济和地缘政治条件、我们开发和营销新产品或改进产品的能力、我们有效竞争的能力、国际法律和监管风险、供应链风险以及产品质量和责任问题。

For further information regarding our risks and uncertainties, please refer to the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

有关我们的风险和不确定性的更多信息，请参阅Bio-Rad向证券交易委员会提交的公开报告中的“风险因素”和“管理层对财务状况和经营成果的讨论和分析”，包括我们最近的10-K表年度报告和10-Q表季度报告。

Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect.

Bio-Rad提醒您不要过度依赖前瞻性陈述，因为这些陈述反映了。